Clinical Trial Update: Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation [Phase 2]

View source ↗

Summary

Phase II study investigating the combination of olaparib and pembrolizumab in metastatic melanoma with homologous recombination mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Olaparib (Olaparib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: California Pacific Medical Center Research Institute | Conditions: Metastatic Melanoma | Phase 2 | Status: UNKNOWN